{"id":"glp-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1240772","moleculeType":"Protein","molecularWeight":"3169.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GLP-2 binds to GLP-2 receptors on intestinal subepithelial myofibroblasts and enteric neurons, triggering increased mesenteric blood flow and stimulating proliferation of intestinal epithelial cells. This mechanism supports intestinal barrier function and nutrient absorption, making it therapeutically relevant for conditions characterized by intestinal dysfunction or mucosal atrophy.","oneSentence":"GLP-2 is a glucagon-like peptide-2 receptor agonist that enhances intestinal blood flow and promotes growth of the intestinal mucosa.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:23.539Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Short bowel syndrome"},{"name":"Intestinal failure-associated liver disease"}]},"trialDetails":[{"nctId":"NCT07349641","phase":"PHASE2","title":"A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-06","conditions":"Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma","enrollment":55},{"nctId":"NCT06751589","phase":"EARLY_PHASE1","title":"A Study of a Weight Loss Intervention in People With Endometrial Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-19","conditions":"Endometrial Cancer","enrollment":36},{"nctId":"NCT07431086","phase":"PHASE2","title":"Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-16","conditions":"Overweight or Obesity","enrollment":120},{"nctId":"NCT07046819","phase":"PHASE2","title":"Tirzepatide in MetALD","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2026-04-01","conditions":"Metabolic Alcohol-associated Liver Disease, Alcohol Use Disorder","enrollment":120},{"nctId":"NCT07497399","phase":"PHASE2","title":"Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04","conditions":"Multiple Sclerosis","enrollment":120},{"nctId":"NCT07284901","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2026-01-12","conditions":"Obesity With Diabetes, Overweight With Diabetes","enrollment":1700},{"nctId":"NCT05933499","phase":"PHASE2","title":"Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-11-05","conditions":"Obesity","enrollment":63},{"nctId":"NCT07446998","phase":"PHASE2","title":"Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","status":"RECRUITING","sponsor":"Veru Inc.","startDate":"2026-03","conditions":"Obesity & Overweight, Mobility Disability, HOMA-IR","enrollment":200},{"nctId":"NCT06732245","phase":"PHASE2","title":"Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese","status":"NOT_YET_RECRUITING","sponsor":"Biomed Industries, Inc.","startDate":"2026-08-15","conditions":"Obesity and Overweight","enrollment":224},{"nctId":"NCT07497880","phase":"PHASE2","title":"Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity","status":"NOT_YET_RECRUITING","sponsor":"Kailera","startDate":"2026-04-01","conditions":"Obesity, Overweight","enrollment":320},{"nctId":"NCT07492563","phase":"","title":"Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay","status":"NOT_YET_RECRUITING","sponsor":"LABORATORIOS INDUFAR","startDate":"2026-03","conditions":"Obesity, Type 2 Diabetes Mellitus, Overweight With Comorbidities","enrollment":300},{"nctId":"NCT06047548","phase":"PHASE3","title":"A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-09-20","conditions":"Overweight, Obesity","enrollment":441},{"nctId":"NCT06651177","phase":"PHASE2","title":"Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"T. John Winhusen, PhD","startDate":"2026-01-29","conditions":"Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":310},{"nctId":"NCT07491133","phase":"NA","title":"Effect of Ambient Temperature on Blood Glucose and Insulin Absorption in Adults With Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2026-03","conditions":"Type 1 Diabetes Mellitus","enrollment":30},{"nctId":"NCT06937099","phase":"PHASE3","title":"Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-06-26","conditions":"Crohn's Disease, Obesity or Overweight","enrollment":290},{"nctId":"NCT07220473","phase":"PHASE2","title":"Tirzepatide to Slow Biological Aging","status":"RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2026-02-27","conditions":"Aging, LONGEVITY 1","enrollment":90},{"nctId":"NCT06143956","phase":"PHASE2","title":"A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-11-17","conditions":"Obesity, Overweight","enrollment":1217},{"nctId":"NCT06439277","phase":"PHASE3","title":"A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-06-03","conditions":"Obesity, Weight Gain","enrollment":300},{"nctId":"NCT06937086","phase":"PHASE3","title":"Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-06-26","conditions":"Ulcerative Colitis, Obesity or Overweight","enrollment":350},{"nctId":"NCT07218445","phase":"PHASE4","title":"The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-04","conditions":"Obesity, Menopause Hot Flashes","enrollment":40},{"nctId":"NCT06037252","phase":"PHASE2","title":"A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-09-21","conditions":"Type 2 Diabetes, Obesity","enrollment":414},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT07165028","phase":"PHASE3","title":"A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease","enrollment":4500},{"nctId":"NCT05663515","phase":"","title":"A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Pancreatic Cancer","enrollment":24000},{"nctId":"NCT06857942","phase":"PHASE4","title":"A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-19","conditions":"Psoriasis, Overweight or Obesity","enrollment":200},{"nctId":"NCT07481747","phase":"PHASE3","title":"Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities","enrollment":2539},{"nctId":"NCT07483801","phase":"PHASE4","title":"DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies","status":"NOT_YET_RECRUITING","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2026-03","conditions":"Cardiovascular Diseases","enrollment":112},{"nctId":"NCT07107334","phase":"PHASE2","title":"A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-03","conditions":"Endometrioid Endometrial Adenocarcinoma","enrollment":20},{"nctId":"NCT07247084","phase":"PHASE4","title":"A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-24","conditions":"Obesity","enrollment":3000},{"nctId":"NCT07281937","phase":"PHASE2","title":"A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verdiva Bio Dev Limited","startDate":"2025-11-25","conditions":"Obesity, Overweight","enrollment":206},{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT05119179","phase":"PHASE4","title":"Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2021-11-22","conditions":"PreDiabetes","enrollment":300},{"nctId":"NCT07207148","phase":"","title":"People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-11-15","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT07195994","phase":"NA","title":"A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes","status":"RECRUITING","sponsor":"QuickSilver Scientific","startDate":"2026-02-05","conditions":"Prediabetes / Type 2 Diabetes","enrollment":90},{"nctId":"NCT06762314","phase":"PHASE2","title":"Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-01-20","conditions":"Diabetes","enrollment":105},{"nctId":"NCT07284979","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2025-12-30","conditions":"Obesity","enrollment":1200},{"nctId":"NCT07257484","phase":"PHASE4","title":"Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors","status":"NOT_YET_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2026-04-06","conditions":"Obesity (Disorder), Breast Cancer","enrollment":30},{"nctId":"NCT07455825","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Healthy Participants","enrollment":64},{"nctId":"NCT07467447","phase":"PHASE2","title":"Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-15","conditions":"Obesity","enrollment":300},{"nctId":"NCT07212868","phase":"PHASE1","title":"The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-02-25","conditions":"Non-Diabetic","enrollment":150},{"nctId":"NCT06252493","phase":"","title":"Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-12-19","conditions":"Crohn Disease","enrollment":25},{"nctId":"NCT07468552","phase":"PHASE2","title":"Trial of Tirzepatide for the Treatment of Cannabis Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2026-11-15","conditions":"Cannabis Use Disorder","enrollment":100},{"nctId":"NCT07465926","phase":"","title":"Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3","status":"COMPLETED","sponsor":"Chung Shan Medical University","startDate":"2017-01-01","conditions":"Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease","enrollment":451036},{"nctId":"NCT07463846","phase":"PHASE1, PHASE2","title":"A Study to Evaluate ALN-2232 in Participants With Obesity","status":"RECRUITING","sponsor":"Alnylam Pharmaceuticals","startDate":"2026-03-02","conditions":"Obesity","enrollment":156},{"nctId":"NCT06982378","phase":"","title":"GLP-1 RA on Liver OMICS in MASLD","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-07","conditions":"NAFLD, Diabetes, Obesity","enrollment":30},{"nctId":"NCT06246799","phase":"PHASE3","title":"Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-11-07","conditions":"Type 2 Diabetes (Adult Onset)","enrollment":256},{"nctId":"NCT07249554","phase":"PHASE2","title":"Combination Therapy for Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-05","conditions":"Alcohol Use Disorder","enrollment":45},{"nctId":"NCT07458269","phase":"PHASE2","title":"Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Kailera","startDate":"2026-03","conditions":"Obesity","enrollment":250},{"nctId":"NCT06162715","phase":"PHASE2, PHASE3","title":"GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2024-10-30","conditions":"Severe Obesity, Obesity, BMI Greater Than 30","enrollment":30},{"nctId":"NCT07457424","phase":"","title":"Direct Measurement of Microstructure of Ingestive Behaviour After Initiation of GLP-1 Receptor Agonist Treatment at Maximum Dose (DIGRAT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College Dublin","startDate":"2022-02-17","conditions":"Metabolic Disease, Obesity & Overweight","enrollment":140},{"nctId":"NCT05965908","phase":"PHASE3","title":"Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-01-30","conditions":"Polycystic Ovary","enrollment":150},{"nctId":"NCT05500586","phase":"PHASE1, PHASE2","title":"The Effects of Glucagon on Hepatic Metabolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adrian Vella","startDate":"2022-10-20","conditions":"Obesity, Type2diabetes, NAFLD","enrollment":21},{"nctId":"NCT05254314","phase":"PHASE2","title":"Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-10-11","conditions":"Asthma","enrollment":100},{"nctId":"NCT06747468","phase":"PHASE3","title":"Avexitide for Treatment of Post-Bariatric Hypoglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2025-04-29","conditions":"Post Bariatric Hypoglycemia","enrollment":75},{"nctId":"NCT07299084","phase":"PHASE1","title":"A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-01-14","conditions":"Diabetes Mellitus, Type 2, Overweight, Obesity","enrollment":40},{"nctId":"NCT05681299","phase":"PHASE4","title":"Effects of GH and Lirglutide on AgRP","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-05-01","conditions":"Healthy, Growth Hormone Deficiency","enrollment":40},{"nctId":"NCT07443956","phase":"NA","title":"Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis","status":"NOT_YET_RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2026-02-24","conditions":"Psoriatic Arthritis (PsA), Obesity & Overweight","enrollment":45},{"nctId":"NCT07284875","phase":"PHASE3","title":"Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes","status":"RECRUITING","sponsor":"Kailera","startDate":"2025-12-18","conditions":"Obesity, Overweight","enrollment":1800},{"nctId":"NCT06512584","phase":"PHASE3","title":"Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition","status":"RECRUITING","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2024-09-03","conditions":"Short Bowel Syndrome","enrollment":72},{"nctId":"NCT07444203","phase":"","title":"Transformative Research in Diabetic Nephropathy 2.0","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-11-12","conditions":"Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic","enrollment":200},{"nctId":"NCT07439536","phase":"PHASE4","title":"Dose Optimization of Sitagliptin and Duloxetine in Diabetic Cirrhosis","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-07-01","conditions":"Liver Cirrhosis With Diabetes","enrollment":64},{"nctId":"NCT07427251","phase":"PHASE4","title":"The Postprandial Hypo-Avoid Study","status":"NOT_YET_RECRUITING","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2026-03-15","conditions":"Type 1 Diabetes Mellitus","enrollment":18},{"nctId":"NCT06759701","phase":"EARLY_PHASE1","title":"Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-02","conditions":"Diabetes, Prostate Cancer","enrollment":30},{"nctId":"NCT07304141","phase":"","title":"Pharmacological Treatment - An Overview of Its Role in Managing Childhood Obesity","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2023-12-20","conditions":"Obesity (Disorder), Child Obesity","enrollment":128},{"nctId":"NCT07438444","phase":"PHASE4","title":"A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-03","conditions":"Diabetes Mellitus, Type 2, Obesity, Overweight","enrollment":344},{"nctId":"NCT06027567","phase":"PHASE4","title":"The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure","status":"COMPLETED","sponsor":"Rigmor Højland Jensen","startDate":"2022-09-02","conditions":"Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity","enrollment":38},{"nctId":"NCT07095517","phase":"PHASE1","title":"Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-02-24","conditions":"Colorectal Cancer Prevention, Colorectal Adenoma","enrollment":20},{"nctId":"NCT06546384","phase":"NA","title":"GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease","status":"NOT_YET_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2026-05-01","conditions":"Adiposity, Fatty Liver, Alcohol Use Disorder","enrollment":64},{"nctId":"NCT07027995","phase":"NA","title":"Food and Fitness With Medicine (FFWM)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2026-01-14","conditions":"Cardiovascular Kidney Metabolic Syndrome, Type 2 Diabetes","enrollment":200},{"nctId":"NCT07317115","phase":"NA","title":"Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes","status":"RECRUITING","sponsor":"GT Metabolic Solutions, Inc.","startDate":"2026-03","conditions":"Obesity (Disorder), Obesity & Overweight, Type 2 Diabetes (T2DM)","enrollment":20},{"nctId":"NCT07423247","phase":"PHASE4","title":"Tirzepatide (Spartina) in Obese Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2026-01-01","conditions":"Tirzepatide","enrollment":30},{"nctId":"NCT07417618","phase":"","title":"INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-01-27","conditions":"Type 2 Diabetes, Overweight, ASCVD","enrollment":60000},{"nctId":"NCT03363464","phase":"","title":"Comparative Effectiveness of Empagliflozin in the US","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2017-10-16","conditions":"Diabetes Mellitus, Type 2","enrollment":230000},{"nctId":"NCT07101939","phase":"PHASE2","title":"A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)","status":"RECRUITING","sponsor":"Actimed Therapeutics Ltd","startDate":"2025-06-23","conditions":"Obesity, Muscle Loss","enrollment":120},{"nctId":"NCT06914895","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-04-25","conditions":"Type 1 Diabetes, Obesity, Overweight","enrollment":905},{"nctId":"NCT06962280","phase":"PHASE3","title":"A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-05-12","conditions":"Type 1 Diabetes, Obesity, Overweight","enrollment":465},{"nctId":"NCT06470295","phase":"EARLY_PHASE1","title":"Effect of C-peptide on Hypoglycemic Counterregulation","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2024-06-01","conditions":"Hypoglycemia, Type 1 Diabetes","enrollment":38},{"nctId":"NCT05264727","phase":"PHASE4","title":"Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-05-30","conditions":"Healthy, Type 2 Diabetes, Obesity","enrollment":30},{"nctId":"NCT07411378","phase":"PHASE2","title":"Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.","status":"NOT_YET_RECRUITING","sponsor":"Biophytis","startDate":"2026-07","conditions":"Muscle Wasting, Obesity & Overweight, Obesity","enrollment":164},{"nctId":"NCT06517212","phase":"PHASE2","title":"Tirzepatide Weight Loss for MRD+ Early Breast Cancer","status":"RECRUITING","sponsor":"Baylor Research Institute","startDate":"2024-11-26","conditions":"Breast Cancer, Breast Neoplasms, Breast Cancers","enrollment":48},{"nctId":"NCT06965413","phase":"PHASE2","title":"A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-05","conditions":"Obesity, Overweight, Overweight With One Weight Related Comorbidity","enrollment":285},{"nctId":"NCT06608433","phase":"NA","title":"Glucagon-like Peptide-1 Receptor Agnoists for the Assessment of Adrenal Function","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-01-16","conditions":"Healthy Volunteer Study, HPA, Cortisol Deficiency","enrollment":22},{"nctId":"NCT06939088","phase":"PHASE2","title":"Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder","status":"RECRUITING","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2025-05-05","conditions":"Alcohol Use Disorder, Alcohol Abuse/Dependence, Alcohol Dependence","enrollment":108},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT07400783","phase":"NA","title":"TED_ORG: Study on Short Bowel Syndrome","status":"RECRUITING","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2024-10-30","conditions":"Short Bowel Syndrome (SBS)","enrollment":50},{"nctId":"NCT06864026","phase":"PHASE4","title":"A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-03-06","conditions":"Psoriatic Arthritis, Overweight or Obesity","enrollment":200},{"nctId":"NCT07398300","phase":"NA","title":"Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2026-03-12","conditions":"Type 2 Diabetes, Healhty","enrollment":36},{"nctId":"NCT02674893","phase":"PHASE4","title":"Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2014-02-04","conditions":"Type 2 Diabetes, Overweight","enrollment":48},{"nctId":"NCT06558422","phase":"PHASE1","title":"Human Models of Selective Insulin Resistance: Pancreatic Clamp","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2027-01-01","conditions":"Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease","enrollment":36},{"nctId":"NCT06131437","phase":"PHASE3","title":"A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-11-27","conditions":"Obesity","enrollment":809},{"nctId":"NCT06986603","phase":"PHASE4","title":"Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Joslin Diabetes Center","startDate":"2024-11-26","conditions":"Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery","enrollment":28},{"nctId":"NCT02721888","phase":"PHASE4","title":"Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2012-07-10","conditions":"Type 2 Diabetes","enrollment":127},{"nctId":"NCT07136714","phase":"PHASE4","title":"Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity","status":"RECRUITING","sponsor":"Nordsjaellands Hospital","startDate":"2025-09-11","conditions":"Major Depressive Disorder","enrollment":116},{"nctId":"NCT07228741","phase":"PHASE2","title":"Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity","status":"NOT_YET_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03","conditions":"Acute Lymphoblastic Leukemia, Obesity","enrollment":20},{"nctId":"NCT03498001","phase":"NA","title":"Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2018-04-16","conditions":"Type II Diabetes","enrollment":42},{"nctId":"NCT07387796","phase":"NA","title":"Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas at Dallas","startDate":"2026-02","conditions":"Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes","enrollment":40},{"nctId":"NCT07246421","phase":"NA","title":"Glucagon Resistance in Patients With MASLD and T2DM","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2026-01-29","conditions":"Metabolic Associated Fatty Liver Disease, Type 2 Diabetes (T2DM)","enrollment":24},{"nctId":"NCT07202247","phase":"PHASE2","title":"Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-01-23","conditions":"Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":60},{"nctId":"NCT07382024","phase":"NA","title":"Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-05-01","conditions":"Atrial Fibrillation Ablation, Persistent Atrial Fibrillation, Obesity & Overweight","enrollment":200},{"nctId":"NCT07366710","phase":"NA","title":"Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-05","conditions":"Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1267,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glucagon like peptide 2"],"phase":"phase_3","status":"active","brandName":"GLP-2","genericName":"GLP-2","companyName":"University of Copenhagen","companyId":"university-of-copenhagen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GLP-2 is a glucagon-like peptide-2 receptor agonist that enhances intestinal blood flow and promotes growth of the intestinal mucosa. Used for Short bowel syndrome, Intestinal failure-associated liver disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}